The 15-20 National Hospital and GenSight Biologics Announce the First Treatments in the French Named Patient Early Access Program (AAC) for GS010/LUMEVOQ®

Core Viewpoint - The National Hospital (l'Hôpital national des 15-20) in Paris and GenSight Biologics have initiated the treatment of the first patients under the French Named Patient Early Access Program for GS010/LUMEVOQ®, marking a significant step in the development of innovative gene therapies for retinal neurodegenerative diseases [1] Group 1 - The collaboration involves the treatment of patients with GS010/LUMEVOQ®, a gene therapy aimed at addressing retinal neurodegenerative diseases and central nervous system disorders [1] - The program is part of an early access initiative, allowing patients to receive treatment before full regulatory approval [1]